IGC Pharma, Inc. (IGC)
NYSEAMERICAN: IGC · Real-Time Price · USD
0.3000
-0.0361 (-10.74%)
At close: Dec 19, 2025, 4:00 PM EST
0.3000
0.00 (0.00%)
After-hours: Dec 19, 2025, 8:00 PM EST
IGC Pharma Employees
IGC Pharma had 70 employees as of March 31, 2025. The number of employees increased by 3 or 4.48% compared to the previous year.
Employees
70
Change (1Y)
3
Growth (1Y)
4.48%
Revenue / Employee
$15,800
Profits / Employee
-$92,086
Market Cap
27.86M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 70 | 3 | 4.48% |
| Mar 31, 2024 | 67 | 6 | 9.84% |
| Mar 31, 2023 | 61 | 9 | 17.31% |
| Mar 31, 2022 | 52 | 2 | 4.00% |
| Mar 31, 2021 | 50 | 0 | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IGC News
- 11 hours ago - IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum - Accesswire
- 4 days ago - IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines - Accesswire
- 9 days ago - IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. - Accesswire
- 10 days ago - IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial - Accesswire
- 17 days ago - IGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer's Disease - Accesswire
- 24 days ago - IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging Trends - Accesswire
- 4 weeks ago - IGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital - Accesswire
- 5 weeks ago - USPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer's Disease and Central Nervous System Disorders - Accesswire